GlobeNewswire Inc | Mar 4, 2021 01:00PM EST

March 04, 2021

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Companys Employee Share Purchase Plan (the ESPP), new 17,652 ordinary shares of 0.0025 each in the capital of the Company (the Ordinary Shares) have been issued to settle the purchase of 8,826 American Depositary Shares, each representing two Ordinary Shares (ADSs) by employees who participated in the ESPP. Further details in relation to the ESPP were contained in the Companys announcement of 2 September 2020.

O. James Sterling, Chief Financial Officer, participated in the plan and acquired 4,596 ordinary shares (2,298 ADSs) at 4.50 per share ($12.563 per ADS).

The purchase of ADSs by certain employees of the Company who are treated as affiliates under U.S. securities laws (including O. James Sterling, Chief Financial Officer) will be settled once certain additional U.S. securities law requirements have been complied with.

An application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 17,652 new Ordinary Shares to trading on AIM will become effective on, or around, 9 March 2021 ("Admission").

Total voting rightsFollowing Admission, the Company will have 72,047,286 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,047,286.

For further information, please contact:

UK Investor Contact: Walbrook PRLimited Tel: 020 7933 8780 orrenalytix@walbrookpr.comPaul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303

US Investor Contact: Gilmartin Group investors@renalytixai.comCarrie Mendivil / Mary Kate McDonough 415-937-5405

About Kidney DiseaseKidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a silent killer because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAIRenalytixAI is a developer of clinical grade, artificial intelligence-enabled in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, and patient stratification for drug clinical trials. For more information, visitrenalytixai.com

Notification of dealings in shares by PDMRs of the Company:

1. Details of PDMR / PDMR Associate(a) Name O. James Sterling(b) Position / status Chief Financial Officer(c) Initial notification / Initial Notification amendment Details of the transaction(s): section to be repeated for (i) each type2. of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted(d) Description of the Acquisition of Ordinary Shares to be converted financial instrument to American Depositary Shares(e) Nature of the transaction Acquisition of shares Price: 4.50(f) Price(s) and volume(s) Volume: 4,596 shares



Aggregated information

(g) Aggregated volume 4,596shares Price 20,682(h) Date of the transaction 4 March 2021(i) Place of the transaction Outside a trading venue